Chlorambucil in Metastatic PDAC Patients Bearing a Germ Line DNA Defects Repair Mutations (SALE Trial)

  • STATUS
    Recruiting
  • End date
    Dec 26, 2023
  • participants needed
    30
  • sponsor
    Michele Reni
Updated on 26 January 2021

Summary

The main objective of this trial is to explore the activity of chlorambucil, an alkylating agent commonly used in chronic lymphocytic leukemia treatment, in metastatic patients, gBRCA, including VUS, or DDR mutated, previously treated with a platinum-containing chemotherapy.

Description

Nowadays, treatment strategies for patients affected by metastatic pancreatic ductal adenocarcinoma (PDAC) are still very scant. Gemcitabine and fluoropyrimidine based chemotherapy regimens are standard I line chemotherapy. Recently, landmark genome-wide studies revealed the existence of a distinct subpopulation of PDAC with highly unstable genomic properties, due to mutations in DNA Damage Repair genes (DDR), in particular BRCA1/2 mutations. Germline mutations cause a deficiency in deoxyribonucleic acid (DNA) damage repair due to inhibition of DNA double-strand breaks repair by the mechanism of homologous recombination. Cancer cells rely on DNA repair to survive the damage induced by genotoxic stress and DNA repair enables cancer cells to accumulate genomic alterations that contribute to their aggressive phenotype. BRCA1/2 abrogation and homologous repair deficiency (HRD) confer sensitivity to DNA damage-inducing drugs, in particular those inflicting cytotoxic DNA crosslinks that interfere with DNA replication. The sensitivity of BRCA1/2-mutated tumors to platinum compounds has been validated in multiple pre-clinical and clinical studies. Nevertheless, similar lesions are induced by DNA-alkylating agents, which include mono-functional (e.g. mitomycin C) or bifunctional alkylators (e.g. chlorambucil). Small molecule inhibitors of poly(ADP-ribose) polymerase (PARP) have been recently developed and they showed an interesting activity and efficacy in breast, ovarian and pancreatic cancer tumors. Although platinum drugs and PARP inhibitors show initially good responses in the clinic, most patients acquire resistance to these drugs. Chlorambucil shows high selective toxicity against human cells and xenograft tumors with compromised BRCA1/2 function. Patients affected by metastatic ductal adenocarcinoma, pretreated with at least one previous platinum-based chemotherapy, will be treated with oral chlorambucil for 42 consecutive days After restaging, responder patients and those with stable disease will receive for 14 consecutive days every 28 days until disease progression (RECIST 1.1 criteria) or unbearable toxicity, patient refusal or medical decision.

Details
Condition Pancreatic Ductal Adenocarcinoma
Treatment Chlorambucil, Oral, 2 Mg
Clinical Study IdentifierNCT04692740
SponsorMichele Reni
Last Modified on26 January 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Pathologically confirmed pancreatic adenocarcinoma
Age 18 years
ECOG PS 0-2
Stage IV disease
Identified genetic aberrations that are associated with homologous recombination deficiency (HRD)
Cohort A: Documented mutation in gBRCA1 or gBRCA2 that is predicted to be deleterious or suspected deleterious
Cohort B: BRCA1 or BRCA2 mutations that are considered to be of uncertain/unknown significance (VUS)
Cohort C: Patients with other identified genetic aberrations that are associated with HRD
Adequate PFS during previous platinum-based chemotherapy for at least 4 months before progression
Screening laboratory values
Leukocytes > 3000/mmc Thrombocytes > 150000/mmc Hemoglobin > 10 g/dl
Creatinine <2.0 times upper normal limit (unless normal creatinine clearance)
Total bilirubin < 2.0 times upper normal limit (unless due to Gilbert's
syndrome)
Alanine aminotransferase (ALT) < 3.0 times upper normal limit
\. Able to take oral medication
\. Progression during or after platinum-based chemotherapy
\. Other prior chemotherapy apart from first-line treatment for pancreatic
cancer, are allowed, including maintenance treatment with PARP inhibitors
\. More than 2 weeks since prior chemotherapy end
\. Signed written informed consent
\. QTc <450 msec or QTc <480 msec for patients with bundle branch block

Exclusion Criteria

Clinically significant cardiac disease including unstable angina, acute myocardial infarction within 6 months prior to screening, congestive heart failure, and arrhythmia requiring therapy, with the exception of extra systoles or minor conduction abnormalities
Active and uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy
Vaccination with vaccines called "live", since this treatment causes a drop of immunity defenses and a serious infection could result fatal
History of seizure, head trauma and treatment with anti-epileptogenic drugs
Hypersensitivity to chlorambucil or to any excipients, in particular lactose
Recent radiotherapy (at least 4 weeks) or previous treatment with other cytotoxic agents
BRCA-mutated advanced pancreatic cancer who did not undergo maintenance with olaparib after platinum-based chemotherapy
Mismatch repair (MMR)/high levels of microsatellite instability (MSI-H), or high levels of tumor mutational burden (TMB) pancreatic cancer who did not undergo immunotherapy with pembrolizumab monotherapy or any other anti-PD1 agent
Concomitant PARP inhibitors therapy
Life expectancy less than 3 months, in the opinion of the investigator
Other past or current malignancy. Subjects who have been free of malignancy for at least 5 years, or have a history of completely resected non-melanoma skin cancer, or successfully treated in situ carcinoma are eligible
Symptomatic duodenal stenosis
CT contrast medium allergy and claustrophobia to RM investigation
Any significant medical condition laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study
Any condition including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study
Any condition that confounds the ability to interpret data from the study
Any familiar, sociologic or geographic conditions that can potentially interfere with the adhesion to the protocol or to the follow-up
Pregnant or nursing. Adequate contraception is defined as oral hormonal birth control, intrauterine device, and male partner sterilization (if male partner is sole partner for that subject) and the double barrier method (condom or occlusive cap plus spermicidal agent)
Concurrent treatment with other experimental drugs
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note